Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
2018 · New England Journal of Medicine · 6,385 citations
https://doi.org/10.1056/nejmoa1801005
S
Shirish M. Gadgeel
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
845
Papers
41.8K
Citations
76
h-index
285
i10-index
Shirish M. Gadgeel is an academic researcher. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Colorectal Cancer Treatments and Studies. The author has an h-index of 76, co-authored 719 publications.
ORCID: 0000-0001-5240-3811Papers by this author
worksAdagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation
2022 · New England Journal of Medicine · 886 citations
https://doi.org/10.1056/nejmoa2204619
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
2021 · Annals of Oncology · 409 citations
https://doi.org/10.1016/j.annonc.2021.04.008
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials
2020 · Journal of Thoracic Oncology · 192 citations
https://doi.org/10.1016/j.jtho.2020.09.022
Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs
2013 · Journal of Hematology & Oncology · 143 citations
https://doi.org/10.1186/1756-8722-6-77
Molecular therapeutic targets in non-small cell lung cancer
2020 · Expert Review of Anticancer Therapy · 86 citations
https://doi.org/10.1080/14737140.2020.1787156
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat